Last Updated: 04/06/07

James H. Doroshow, M.D., FACP
Director of the Division of Cancer Treatment and Diagnosis

Integrating Therapeutic Development

These efforts also support an NCI-wide priority to better integrate preclinical and clinical research. In addition to partnering with intramural researchers in CCR, DCTD is working to link preclinical and clinical resources seamlessly within the division. This will support extramural trials of targeted therapies and foster better assimilation of molecular imaging and radiation techniques into therapeutics development. Teams of experts across NCI will unite to form integrated drug development teams. A joint CCR-DCTD drug development committee will oversee these teams, determine resource priorities, assess agent progress, identify gaps in the portfolio particularly suited to NCI drug development efforts, and evaluate new compounds for inclusion in the pipeline.

The steps being taken to implement the CTWG initiatives, modernize and integrate cancer therapeutics development using the exploratory IND and other approaches, and expand the pipeline of potential cancer therapies underscore NCI’s position as a premier developer of novel cancer therapeutics and diagnostics.